ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma.

ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma. Chem Pharm Bull (Tokyo). 2020;68(3):194-200 Authors: Sekimata K, Sato T, Sakai N Abstract Fibrodysplasia ossificans progressiva (FOP) and diffuse intrinsic pontine glioma (DIPG) are diseases that typically manifest in childhood and are associated with severely reduced life expectancy. However, there are currently no effective therapies for these diseases, which remain incurable. Activin receptor-like kinase-2 (ALK2), encoded by the ACVR1 gene, is a bone morphogenetic protein (BMP) type-I receptor subtype that plays an important physiological role in the development of bones, muscles, brain, and other organs. Constitutively active mutants of ALK2 have been identified as causative of FOP and involved in the tumorigenesis of DIPG owing to abnormal activation of BMP signaling, and therefore have emerged as promising treatment targets. Here, we describe these two diseases, along with the link to ALK2 signal transduction, and highlight potential ALK2 inhibitors that are under development to offer new hope for patients with FOP and DIPG. PMID: 32115526 [PubMed - in process]
Source: Chemical and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Tags: Chem Pharm Bull (Tokyo) Source Type: research

Related Links:

This study aimed to investigate the association of high-sensitivity C-reactive protein (hsCRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) serum concentrations with cognitive functions of glioma and meningioma patients. Methods: 177 brain tumor patients awaiting for brain tumor surgery participated in the study. Patients were assessed preoperatively, using neuropsychological tests for verbal memory, psychomotor speed, mental flexibility, and verbal fluency. The functional status of patients was evaluated using the Karnofsky Performance Index. Blood samples were drawn for evaluation of serum hsCRP and NT-...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Publication date: Available online 28 May 2020Source: CellAuthor(s): Florian Klemm, Roeltje R. Maas, Robert L. Bowman, Mara Kornete, Klara Soukup, Sina Nassiri, Jean-Philippe Brouland, Christine A. Iacobuzio-Donahue, Cameron Brennan, Viviane Tabar, Philip H. Gutin, Roy T. Daniel, Monika E. Hegi, Johanna A. Joyce
Source: Cell - Category: Cytology Source Type: research
Conclusion: Decreased expression of miR-33b serves a promising biomarker in the diagnosis and prognosis of glioma, and may be a potential therapeutic target. PMID: 32462908 [PubMed - as supplied by publisher]
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
Condition:   Glioma Intervention:   Device: PET/CT, H-MRS and MRI Sponsor:   Tao Xin Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract According to the WHO classification criteria, the most common intracranial tumor gliomas can be divided into four grades based on their symptoms. Among them, Grade Ⅰ and Grade II are low-grade gliomas, and Grade III and Grade IV are high-grade gliomas. Because gliomas have a high lethal rate, they have received widespread attention in the medical field. Based on these circumstances, a rapid and facile surface enhanced Raman scattering (SERS) method using silver nano particle-decorated silver nanorod (AgNPs@AgNR) as substrates were developed for the discrimination of gliomas. Compared with SERS-active si...
Source: Talanta - Category: Chemistry Authors: Tags: Talanta Source Type: research
Abstract Mutant activin receptor-like kinase-2 (ALK2) was reported to be closely associated with the pathogenesis of fibrodysplasia ossificans progressiva (FOP) and diffuse intrinsic pontine glioma (DIPG), and therefore presents an attractive target for therapeutic intervention. Through in silico virtual screenings and structure-activity relationship studies assisted by X-ray crystallographic analyses, a novel series of bis-heteroaryl pyrazole was identified as potent inhibitors of ALK2 (R206H). Derived from in silico hit compound RK-59638 (6a), compound 18p was identified as a potent inhibitor of ALK2 (R206H) wit...
Source: Chemical and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Tags: Chem Pharm Bull (Tokyo) Source Type: research
In this study, we characterized the ALK2 mutants R258G, G328V and F246Y, which were identified in patients with severe FOP, DIPG and unusual hereditary skeletal dysplasia, respectively. Both R258G and G328V were gain-of-function mutations, but F246Y was equivalent to wild-type ALK2.
Source: Bone - Category: Orthopaedics Authors: Tags: Full Length Article Source Type: research
Gain-of-function mutations in the Type I Bone Morphogenic Protein (BMP) receptor ACVR1 have been identified in two diseases: Fibrodysplasia Ossificans Progressiva (FOP), a rare autosomal dominant disorder characterized by genetically driven heterotopic ossification, and in 20 –25% of Diffuse Intrinsic Pontine Gliomas (DIPGs), a pediatric brain tumor with no effective therapies and dismal median survival. While the ACVR1 mutation is causal for FOP, its role in DIPG tumor biology remains under active investigation.
Source: Bone - Category: Orthopaedics Authors: Tags: Full Length Article Source Type: research
Abstract Activin receptor-like kinase 1 (ALK1, encoded by the gene ACVRL1) is a type I BMP/TGF-β receptor that mediates signalling in endothelial cells via phosphorylation of SMAD1/5/8. During angiogenesis, sprouting endothelial cells specialise into tip cells and stalk cells. ALK1 synergises with Notch in stalk cells to induce expression of the Notch targets HEY1 and HEY2 and thereby represses tip cell formation and angiogenic sprouting. The ALK1-Fc soluble protein fusion has entered clinic trials as a therapeutic strategy to sequester the high-affinity extracellular ligand BMP9. Here, we determined the crys...
Source: Angiogenesis - Category: Molecular Biology Source Type: research
More News: Brain | Brain Tumor | Chemistry | Child Development | Drugs & Pharmacology | Fibrodysplasia Ossificans Progressiva | Genetics | Glioma | Neurology